In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC.   This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib.
 
Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo

Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case involving drug resistance in EGFR mutant NSCLC. This discussion takes the listener through the treatment of EGFR mutant NSCLC after acquired resistance to osimertinib. Guest: Dr. Yasushi Goto from National Cancer Center, Japan in Tokyo Guest: Dr. Rachel Sanborn, the Earle A. Chiles Research Institute of the Providence Cancer Institute in Portland, Oregon

Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Science

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 6,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. Lung Cancer considered is funded in part by AstraZeneca, Daiichi Sankyo, Inc., and Takeda

Share Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance

Sign up to save your podcasts

Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance

Virtual Tumor Board: Treating EGFR NSCLC After TKI Resistance

More shows like Lung Cancer Considered

Lung Cancer Update

Freakonomics Radio

NEJM This Week

Hidden Brain

ASCO Daily News

The Daily

Today, Explained

ASCO Guidelines

OncLive® On Air

Plenary Session

Oncology Today with Dr Neil Love

Conversations in Lung Cancer Research

The Ezra Klein Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions